Year All20252024202320222021202020192018201720162015201420122011 Jun 18, 2014 Ardelyx Announces Pricing of its Initial Public Offering May 15, 2014 Ardelyx Receives $25 Million Milestone From AstraZeneca For Commencement Of Phase 2b Clinical Trial Of Tenapanor Feb 24, 2014 Ardelyx Licenses NaP2b Phosphate Inhibitor Program for Kidney Disease to Sanofi in Deal Worth Up to $198 Million. Jan 13, 2014 Ardelyx Receives $15 Million Milestone as Part of Ongoing Tenapanor Collaboration with AstraZeneca Oct 8, 2012 AstraZeneca and Ardelyx Announce Worldwide Licensing Deal For NHE3 Inhibitor Programme For Complications Of Renal Disease, Including Diabetes-Induced Renal Disease. May 24, 2012 Ardelyx will present at the 22nd European Meeting on Hypertension and Cardiovascular Protection in London (UK) April 26-29, 2012 Apr 1, 2012 "Non-systemic drugs: a critical review" published in Current Pharmaceutical Design Aug 31, 2011 Ardelyx Appoints Mark Kaufmann to Chief Business Officer Aug 31, 2011 Ardelyx, Inc. Closes $30M Series B Financing